Table 5.
ICG-antibodies complexation
| Ligand/Target | Target | Type of ICG | Tumor nature | Cell types | In vivo model | Administration routes | References |
|---|---|---|---|---|---|---|---|
| Panitumumab | EGFR/HER-1 | ICG- sulfo-OSu | Colorectal carcinoma | LS-174T cells | Female athymic nude mice | Intravenous injection | (88) |
| Panitumumab | EGFR/HER-1 | ICG-Sulfo-OSu | Breast cancer | MDA-MB-468 | Female athymic nude mice | Tail vein injection | (86) |
| Panitumumab | EGFR/HER-1 | Amine-reactive PEGylated ICG | Squamous carcinoma | A431 cells | – | – | (87) |
| Daclizumab, trastuzumab, panitumumab | IL2R α-chain, HER-2, EGFR/HER-1 | ICG-Sulfo-OSu | – | ATAC4, A431, MDA-MB468, NIH3T3 cells | Mice | Intravenous injection | (33) |
| J591 | PSMA | ICG-Sulfo-OSu | Prostate cancer | PC3 cells | Athymic nude mice | Tail vein injection | (85) |
| Anti- αvβ6 antibody | Integrin αvβ6 | ICG-NHS | Squamous carcinoma | A431 cells | Female nude mice | Tail vein injection | (93) |
Abbreviations: ICG- sulfo-OSu, ICG-N-hydroxysulfosuccinimide ester; PSMA, anti-prostate specific membrane antigen.